June 10, 2021 7:56am

I am, new highs can be anticlimactic

Annual Oncology (ASCO) Meetings and presentations this week

Pre-open indications: 3 BUYs: AGTC, BLCM, SAGE; 2 SELLs into Strength - Profit: CRSP, MESO; 1 Maintain SELLs: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  


Dow futures are UP +0.07% (+24 points), S&P futures are DOWN -0.06% (+3 point) and NASDAQ futures are DOWN -0.37% (-51 points)

 

Futures contracts are mixed on Thursday pre-open.

European stocks were mixed,

Asia-Pacific stocks edged higher

 

Data Docket: consumer price index data at 8:30 a.m. ET on Thursday. Economists expect the May CPI report to show prices up 4.7% year over year after April’s increase of 4.2%.

 

Henry’omics:

U.S. markets continued to trade within a tight range on Wednesday, with all three major indexes ending the day within 0.5% of Tuesday’s closing levels.

Investors have been worried whether inflation would/could prompt the Fed to curb the pace of its asset purchases or begin to signal an increase to interest rates. Still, some say those fears are premature and that the central bank will give markets plenty of time before it makes any moves.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date …  https://www.regmedinvestors.com/articles/11628

 

Wednesday’s evening’s recap: “volatility was in our favor as the cell and gene therapy sector kept to the trend. Some sessions, the trend is our friend and then suddenly it isn't?” … https://www.regmedinvestors.com/articles/11948

  • The Nasdaq closed DOWN -13.16 points (-0.09%);
  • The IBB closed up +1.54% and XBI closed up +0.94%
  • Sector volume was WEAK with 2 of the 22-upside having higher than the 3-month average volume with the volume of 3 of 12-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.82 points or +4.80% at 17.89
  • Wednesday’s percentage (%) of the 22-upside were +0.08% (IONS) to +4.19% (ALNY) while the 12-downside ranges from -0.42% (PGEN) to -7.69% (RENE.L);

Q2/21:

June: 5 positive and 2 negative close

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed up +$0.13 to $1.26 with 1,216 shares traded after Tuesday’s -$0.17 to $1.13 with 2,320 shares traded, Friday’s +$0.19 to $1.30 with 800 shares traded, Thursday’s flat with 3,528 shares traded and last Wednesday’s -0.11 to $1.11 with 5,673 shares traded.

Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

SELL into Strength: for profit …

CRISPR Therapeutics (CRSP) closed up +$$1.07 to $119.98 after Tuesday’s -$0.29 to $118.91 and Monday’s +$5.91 to $119.20 and Friday’s +$3.16 to $113.29 and has a negative -$0.30 or -0.25% pre-market indication.

Mesoblast (MESO) closed up +$0.22 to $7.83 after Tuesday’s +$0.54 to $7.61 and has a positive +$0.02 or +0.26% premarket indication.

 

Maintaining BUY:

Applied Genetic Technologies (AGTC) closed up +$0.11 to $4.28 after Tuesday’s +$0.01 to $4.17 after Monday’s +$0.12 to $4.16 with a positive +$0.15 or +3.50% pre-market indication.

Bellicum Pharmaceuticals (BLCM) closed up +$0.16 to $3.34 and has a positive +$0.06 or +1.80% pre-market indication.

Sage Therapeutics (SAGE) closed up +$0.41 to $75.17 after Tuesday’s +$4.29 to $74.76 and has a positive +$0.83 or +1.10% aftermarket indication.

 

The BOTTOM LINE: If you are trying to gauge if higher share prices are just temporary or about to be deflated?

Wake-up volatility is NOT going away!

I continue to MAINTAIN, this is a confused sector as sentiment fades, momentum is usurped, fundamentals are being ignored – or is it a test of our staying power in certain equities.

It’s going be a long hot summer – expects the fizzle on stock pricing until it isn’t!

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.